Graham Capital Management
LRMR icon

Graham Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Graham Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.8K Sell
12,407
-22,031
-64% -$87.5K ﹤0.01% 1210
2026
Q1 		$155K Sell
34,438
-7,817
-18% -$31.2K ﹤0.01% 995
2025
Q4 		$161K Buy
+42,255
New +$164K ﹤0.01% 1087
2025
Q1 		– Sell
-14,078
Closed -$54.5K – 1415
2024
Q4 		$54.5K Buy
+14,078
New +$92.9K ﹤0.01% 1177

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Graham Capital Management's LRMR Position: Q2 2026 in Review

Graham Capital Management reduced its Larimar Therapeutics (LRMR) stake by 64% in Q2 2026, selling an estimated $87.5K and leaving 12,407 shares worth $37.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1210.

Graham Capital Management first reported a position in LRMR in Q4 2024 and has held it in 4 quarters since. The position peaked at $161K in Q4 2025. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Graham Capital Management held 12,407 shares of Larimar Therapeutics worth $37.8K as of Q2 2026.
  • Graham Capital Management sold 22,031 Larimar Therapeutics shares in Q2 2026, an estimated $87.5K.
  • Larimar Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1210 holding.
  • Graham Capital Management first reported a position in Larimar Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Graham Capital Management's Larimar Therapeutics position peaked at $161K in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.